High-Dose IV Vitamin C: The Trial That Doubled Pancreatic Cancer Survival

The Bottom Line

High-dose intravenous vitamin C (IVC) is the most evidence-backed repurposed cancer treatment available today. A Phase II randomized controlled trial at the University of Iowa doubled overall survival in metastatic pancreatic cancer when added to standard chemotherapy. The mechanism is well-characterized, the safety profile is excellent (with one important screening requirement), and multiple trials across different cancer types show consistent signals.

What It Is

This is not the vitamin C in your orange juice. At pharmacological doses (15-100+ grams per IV infusion), vitamin C acts as a pro-oxidant, which is the opposite of its normal antioxidant role. Oral vitamin C cannot achieve these plasma concentrations due to intestinal absorption limits. The treatment requires IV administration in a clinical setting.

How It Works

At plasma concentrations above 1 mM (achievable only via IV), vitamin C generates hydrogen peroxide (H₂O₂) in tumor tissue through iron-dependent Fenton chemistry. Cancer cells are selectively vulnerable because they contain high levels of intracellular iron and low levels of catalase (the enzyme that neutralizes H₂O₂). Normal cells have adequate catalase and are protected.

Beyond the direct pro-oxidant kill mechanism, IVC also:

Epigenetic regulation: Acts as a cofactor for TET enzymes (DNA demethylation) and Jumonji-C histone demethylases, potentially reactivating silenced tumor suppressor genes
Immune enhancement: Boosts T-cell and NK-cell function
HIF-1α inhibition: Counters the tumor's ability to adapt to low oxygen
EMT reversal: Reverses epithelial-mesenchymal transition (a process cancers use to become invasive)

The Key Trial: Iowa Phase II RCT (2024)

The University of Iowa conducted a Phase II randomized controlled trial in patients with metastatic pancreatic cancer, one of the deadliest cancer types (typical survival with standard chemo: ~8 months).

Design: Patients randomized to gemcitabine/nab-paclitaxel + high-dose IVC vs. chemotherapy alone
Result: The IVC group had doubled overall survival compared to the chemo-alone group
Significance: For context, in metastatic pancreatic cancer, almost nothing moves the survival needle. Doubling it is remarkable for any intervention, let alone an unpatentable vitamin.

Other Human Trial Data

Phase I/IIa Pancreatic Cancer (Nature Scientific Reports, 2017): IVC + gemcitabine. Median overall survival 15.1 months vs. historical ~6 months. Inhibited metastasis markers.
Ovarian Cancer Pilot RCT (Ma et al., 2014): IVC + carboplatin/paclitaxel reduced chemotherapy toxicity and trended toward improved survival.
Prostate Cancer Phase II (Cancer Research Communications, 2024): IVC + docetaxel in metastatic castration-resistant prostate cancer. Confirmed safety; efficacy results mixed.
Systematic Reviews (PMC6071214, PMC8557029): Confirmed safety across 37+ studies. Efficacy signals across pancreatic, ovarian, colorectal, lung, and glioblastoma.

Typical Protocol (From Clinical Trials)

1.0-1.5 g/kg body weight, 2-3 times per week via IV infusion
Typical dose: 75-100g per infusion (for a 70kg person)
Infusion duration: 1.5-3 hours
Often combined with standard chemotherapy

Critical Safety Note: G6PD Screening

You must screen for G6PD deficiency before starting IVC. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic condition affecting ~400 million people worldwide (more common in people of African, Mediterranean, and Asian descent). In G6PD-deficient individuals, high-dose vitamin C can trigger hemolytic crisis, which is a life-threatening destruction of red blood cells.

A simple blood test rules this out. Any clinic offering IVC should require this screening. If they don't, find a different clinic.

Other Risks

Osmotic diuresis (temporary, during infusion)
Kidney stones (oxalate risk, mainly in those with renal impairment)
Mild fatigue and nausea during infusion (self-limiting)
False blood glucose readings (interferes with some glucometers)
Theoretical timing concern with certain chemotherapy drugs (alkylating agents)

Where to Get It

IVC is offered by many integrative oncology clinics. Typical cost: $100-250 per infusion. It is not covered by most insurance plans. Many oncologists are aware of the Iowa trial data and are open to discussing IVC as adjunctive therapy.

Why It's Not Mainstream

Vitamin C is unpatentable. No pharmaceutical company will invest $100M+ in Phase III trials for a compound they can't exclusively sell. The Iowa trial was funded by the NIH, not industry. This is the fundamental barrier to adoption for most repurposed treatments: the evidence can get to Phase II, but the business model for Phase III doesn't exist.

Our Assessment

This is the strongest candidate on our entire list. A randomized controlled trial doubling survival in one of the deadliest cancers is hard to argue with. The mechanism is well-characterized, safety is excellent (with G6PD screening), and it's being used right now in clinical practice. The main barrier is that it requires IV administration. Anyone with cancer should discuss this with their oncologist.

Sources

University of Iowa Phase II RCT (2024): medicine.uiowa.edu
PMC8557029: Comprehensive review of IVC in cancer (2021)
Nature Scientific Reports 2017;7:17188: Pancreatic cancer Phase I/IIa
PMC6071214: Systematic review of IVC clinical trials
Cancer Research Communications 2024;4(8):2174: Prostate cancer RCT